Enveda raises $311 million in Series E funding led by Catalio Capital Management to advance its AI-driven drug discovery efforts.
Amount Raised
$311 Million
Round Type
Series E
BoulderOtherBiotechnologyInvestors
Description
Enveda, a clinical-stage biotechnology company, has closed a $311 million Series E financing round. The round was led by Catalio Capital Management and included investments from various prominent investors. The funding will be used to enhance the company's ability to discover medicines using AI technology. This significant capital injection marks a key milestone in Enveda's journey to revolutionize pharmaceuticals.
Quick answer
Enveda Therapeutics, Inc. raised $311 Million in a Series E round, dated September 23, 2026. Investors: Alderline Group, Sovereign Wealth Fund, Digitalis Ventures, Durable Capital Partners, Iconiq, Lightspeed, Surveyor Capital and T. Rowe Price Investment Management. Enveda Therapeutics, Inc. is based in Boulder, Colorado, United States.
- How much did Enveda Therapeutics, Inc. raise?
- Enveda Therapeutics, Inc. raised $311 Million in a Series E round on September 23, 2026.
- Who invested in Enveda Therapeutics, Inc?
- Alderline Group, Sovereign Wealth Fund, Digitalis Ventures, Durable Capital Partners, Iconiq, Lightspeed, Surveyor Capital and T. Rowe Price Investment Management are named as investors in this round.
- What does Enveda Therapeutics, Inc. do?
- Enveda Biosciences is a biotechnology company building the first high-resolution chemical map of the natural world to tackle the toughest problems in drug discovery.
- Where is Enveda Therapeutics, Inc. based and how big is it?
- Enveda Therapeutics, Inc. is based in Boulder, Colorado, United States. Fundz records about 387 employees.
- Who are the decision-makers at Enveda Therapeutics, Inc?
- Fundz holds 5 contacts at Enveda Therapeutics, Inc., including the Associate Director Operations. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Enveda Therapeutics, Inc. that raised within 45 days of this round, from Fundz verified event records.
- BioVie raised $4.7M (Post-IPO Equity) on November 6, 2026.
- Alethio raised $90M (Series A) on November 5, 2026.
- altM raised $10M (Series A) on November 5, 2026.
- FluoRok raised $30M (Series A) on November 5, 2026.
- T-Therapeutics raised $133M (Series B) on November 5, 2026.
- Venomics AI raised $2.7M (Pre-Seed) on November 5, 2026.
Who to call at Enveda Therapeutics, Inc., and when
A new round usually means Enveda Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Enveda Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Enveda Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Enveda Therapeutics, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Enveda Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Enveda Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.